<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>Wiley-Blackwell</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24843781</article-id><article-id pub-id-type="pmc">4020337</article-id><article-id pub-id-type="doi">10.1111/jdi.12151</article-id><article-id pub-id-type="publisher-id">JDI12151</article-id><article-categories><subj-group subj-group-type="overline"><subject>Clinical Trial</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparison of the efficacy of sitagliptin and glimepiride dose&#x02010;up in <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination</article-title><alt-title alt-title-type="left-running-head">Shimoda <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12151-cr-0001" contrib-type="author"><name><surname>Shimoda</surname><given-names>Seiya</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref><xref ref-type="author-note" rid="jdi12151-note-0001"><sup>&#x02020;</sup></xref></contrib><contrib id="jdi12151-cr-0002" contrib-type="author"><name><surname>Iwashita</surname><given-names>Shinsuke</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref><xref ref-type="author-note" rid="jdi12151-note-0001"><sup>&#x02020;</sup></xref></contrib><contrib id="jdi12151-cr-0003" contrib-type="author"><name><surname>Sekigami</surname><given-names>Taiji</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0002"><sup>2</sup></xref></contrib><contrib id="jdi12151-cr-0004" contrib-type="author"><name><surname>Furukawa</surname><given-names>Noboru</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0005" contrib-type="author"><name><surname>Matsuo</surname><given-names>Yasuto</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0003"><sup>3</sup></xref></contrib><contrib id="jdi12151-cr-0006" contrib-type="author"><name><surname>Ichimori</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0004"><sup>4</sup></xref></contrib><contrib id="jdi12151-cr-0007" contrib-type="author"><name><surname>Goto</surname><given-names>Rieko</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0008" contrib-type="author"><name><surname>Maeda</surname><given-names>Takako</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0009" contrib-type="author"><name><surname>Watanabe</surname><given-names>Eiichiro</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0005"><sup>5</sup></xref></contrib><contrib id="jdi12151-cr-0010" contrib-type="author"><name><surname>Kondo</surname><given-names>Tatsuya</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0011" contrib-type="author"><name><surname>Matsumura</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0012" contrib-type="author"><name><surname>Motoshima</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12151-cr-0013" contrib-type="author"><name><surname>Nishida</surname><given-names>Kenro</given-names></name><xref ref-type="aff" rid="jdi12151-aff-0006"><sup>6</sup></xref></contrib><contrib id="jdi12151-cr-0014" contrib-type="author"><name><surname>Araki</surname><given-names>Eiichi</given-names></name><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="jdi12151-aff-0001"><sup>1</sup></xref></contrib></contrib-group><aff id="jdi12151-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Metabolic Medicine</named-content><named-content content-type="organisation-division">Faculty of Life Sciences</named-content><institution>Kumamoto University</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><aff id="jdi12151-aff-0002"><label><sup>2</sup></label><institution>Kumamoto Social Insurance General Hospital</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><aff id="jdi12151-aff-0003"><label><sup>3</sup></label><institution>Saiseikai Kumamoto Hospital</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><aff id="jdi12151-aff-0004"><label><sup>4</sup></label><institution>Ueki Hospital</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><aff id="jdi12151-aff-0005"><label><sup>5</sup></label><institution>Kumamoto Chuo Hospital</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><aff id="jdi12151-aff-0006"><label><sup>6</sup></label><institution>Minamata City Hospital and Medical Center</institution><named-content content-type="city">Kumamoto</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Corresponding author. Eiichi Araki Tel.: +81&#x02010;96&#x02010;373&#x02010;5169 Fax: +81&#x02010;96&#x02010;366&#x02010;8397<break/>
E&#x02010;mail address: <email>earaki@gpo.kumamoto-u.ac.jp</email><break/></corresp><fn id="jdi12151-note-0001" fn-type="con"><label>&#x02020;</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="ppub"><day>04</day><month>5</month><year>2014</year></pub-date><volume>5</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/jdi.2014.5.issue-3</issue-id><fpage>320</fpage><lpage>326</lpage><history><date date-type="received"><day>19</day><month>4</month><year>2013</year></date><date date-type="rev-recd"><day>05</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2014 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd</copyright-statement><copyright-statement content-type="article-copyright">&#x000a9; 2013 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:jdi-5-320.pdf"/><abstract abstract-type="main" id="jdi12151-abs-0001"><title>Abstract</title><sec id="jdi12151-sec-0001"><title>Aims/Introduction</title><p>The goal of the study was to examine the effects of sitagliptin dose&#x02010;up or glimepiride dose&#x02010;up in <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes who were controlled inadequately by sitagliptin and glimepiride in combination.</p></sec><sec id="jdi12151-sec-0002"><title>Materials and Methods</title><p>A multicenter, prospective, randomized, open&#x02010;label study was carried out in 50 patients with type 2 diabetes treated with sitagliptin and low&#x02010;dose glimepiride. The patients were randomly assigned to receive the addition of 50&#x000a0;mg/day sitagliptin or 0.5&#x000a0;mg/day glimepiride. The primary end&#x02010;point was the percentage change in glycated hemoglobin (<styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c).</p></sec><sec id="jdi12151-sec-0003"><title>Results</title><p>During a follow&#x02010;up period, the difference in the percentage changes in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c between the two groups was not significant (<italic>P</italic>&#x000a0;=&#x000a0;0.13). However, <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c was significantly decreased by glimepiride dose&#x02010;up (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 vs baseline), but not by sitagliptin dose&#x02010;up (<italic>P</italic>&#x000a0;=&#x000a0;0.74). Univariate linear regression analyses showed that the percentage change in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c was significantly associated with the serum level of arachidonic acid (<styled-content style="fixed-case">AA</styled-content>) in both groups.</p></sec><sec id="jdi12151-sec-0004"><title>Conclusions</title><p>There was no significant difference in the <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c&#x02010;lowering effects between the two groups. However, a significant <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c&#x02010;lowering effect from baseline of glimepiride dose&#x02010;up was found, and the <styled-content style="fixed-case">AA</styled-content> level showed a negative correlation with the decrease in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c in the sitagliptin dose&#x02010;up group, but a positive correlation in the glimepiride dose&#x02010;up group. These findings suggest that the <styled-content style="fixed-case">AA</styled-content> level is associated with <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c reduction in response to dose&#x02010;up with these drugs in patients with type 2 diabetes in a combination therapy with sitagliptin and glimepiride. This trial was registered with <styled-content style="fixed-case">UMIN</styled-content> (no. 000009544).</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12151-kwd-0001">Arachidonic acid</kwd><kwd id="jdi12151-kwd-0002">Glimepiride</kwd><kwd id="jdi12151-kwd-0003">Sitagliptin</kwd></kwd-group><counts><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12151</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2014</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLM version:4.0.3 mode:remove_FC converted:04.05.2014</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation"><mixed-citation publication-type="self-citation" id="jdi12151-cit-1001"><source>J Diabetes Invest</source><year>2014</year>; 5: 320&#x02013;326</mixed-citation></p></notes></front><body><sec sec-type="intro" id="jdi12151-sec-0005"><title>Introduction</title><p>Type 2 diabetes is a chronic disease that usually requires treatment with multiple antihyperglycemic agents (AHAs) during the course of the disease. The American Diabetes Association/European Association for the Study of Diabetes algorithm for treating type 2 diabetes recommends metformin as initial monotherapy<xref rid="jdi12151-bib-0001" ref-type="ref">1</xref>. In contrast, insulin secretion capacity is genetically lower in Japanese subjects than in Caucasians. Therefore, sulfonylureas (SUs) are frequently used in treatment in approximately 60% of type 2 diabetes patients in Japan<xref rid="jdi12151-bib-0002" ref-type="ref">2</xref>. However, SUs often increase the risks of hypoglycemia and weight gain resulting in deterioration of glycemic control in the long term.</p><p>A dipeptidylpeptidase&#x02010;4 (DPP&#x02010;4) inhibitor is an AHA that prevents degradation of glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) and gastric inhibitory polypeptide (GIP)<xref rid="jdi12151-bib-0003" ref-type="ref">3</xref>. Six different DPP&#x02010;4 inhibitors are available in Japan: sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin and anagliptin. Among these agents, sitagliptin is the most widely used, because it was the first DPP&#x02010;4 inhibitor approved in Japan, and its efficacy and safety are proved in Japanese clinical practice<xref rid="jdi12151-bib-0004" ref-type="ref">4</xref>. Sitagliptin might be more effective for glycemic control in Japanese patients as compared with Caucasian patients<xref rid="jdi12151-bib-0005 jdi12151-bib-0006 jdi12151-bib-0007" ref-type="ref">5</xref>. Sitagliptin does not increase the incidence of hypoglycemia when used as monotherapy or with agents that do not cause hypoglycemia, such as metformin and thiazolidinediones, but might increase the incidence when used with agents that cause hypoglycemia<xref rid="jdi12151-bib-0008" ref-type="ref">8</xref>. The first report of severe hypoglycemia in a Japanese patient treated with sitagliptin combined with SUs was described in a case in which 50&#x000a0;mg/day sitagliptin was added to 6&#x000a0;mg/day glimepiride<xref rid="jdi12151-bib-0009" ref-type="ref">9</xref>. Since then, there have been more than 70 reported cases of severe hypoglycemia within a week after initiation of combination therapy with sitagliptin and SUs<xref rid="jdi12151-bib-0010" ref-type="ref">10</xref>. In most of these cases, a relatively high dose of SUs was administered to elderly patients who also had mild renal dysfunction. This led to establishment of a committee of diabetologists to examine the appropriate use of incretin&#x02010;based therapy. This committee recommended that the SU dose should be no more than 1.25&#x000a0;mg/day glibenclamide, 2.0&#x000a0;mg/day glimepiride or 40&#x000a0;mg/day gliclazide at the initiation of incretin&#x02010;based therapy<xref rid="jdi12151-bib-0011" ref-type="ref">11</xref>.</p><p>Since this recommendation was established in Japan, the number of cases of severe hypoglycemia has decreased markedly, and it was reported that combination therapy with sitagliptin and a low dosage of SUs was safe and effective for glycemic control<xref rid="jdi12151-bib-0004" ref-type="ref">4</xref>. However, the effect of glimepiride dose&#x02010;up or sitagliptin dose&#x02010;up on glycemic control in patients with type 2 diabetes controlled inadequately by a combination therapy with sitagliptin and a low&#x02010;dose of glimepiride has not been determined. The standard initial dose of sitagliptin in Japan is 50&#x000a0;mg/day, and sitagliptin 50&#x000a0;mg/day dose&#x02010;up in patients who are poorly controlled with 50&#x000a0;mg/day sitagliptin is common in Japan, because the maximum recommended dosage of sitagliptin is 100&#x000a0;mg/day. The minimum dosage of glimepiride is 0.5&#x000a0;mg, and the maximum is 6&#x000a0;mg/day. Therefore, we carried out a prospective study to investigate the efficacy of the addition of 50&#x000a0;mg/day sitagliptin (maximum dose&#x02010;up) or 0.5&#x000a0;mg/day glimepiride (minimum dose&#x02010;up) for glycemic control in Japanese patients treated with a combination therapy.</p><p>Recently, Iwasaki <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0012" ref-type="ref">12</xref> showed that alterations in the glycated hemoglobin (HbA1c) level on administration of DPP&#x02010;4 inhibitors as monotherapy are associated with estimated intake of fish, estimated intake of dietary n&#x02010;3 polyunsaturated fatty acids (PUFAs), and serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), but not with arachidonic acid (AA). Accordingly, the relationships between the percentage change in HbA1c and serum levels of PUFAs (AA, EPA, DHA and EPA/AA ratio) were also determined.</p></sec><sec sec-type="materials|methods" id="jdi12151-sec-0006"><title>Materials and Methods</title><sec id="jdi12151-sec-0007"><title>Participants and Study Design</title><p>The present study was carried out as a prospective, multicenter, randomized, open&#x02010;label, parallel&#x02010;group, intervention trial in 50 patients with type 2 diabetes who visited our medical institutions as outpatients. The study was designed in accordance with the principles stated in the Declaration of Helsinki. All participants gave written informed consent. The protocol was approved by the ethics committee of Kumamoto University (approval number 1469). This trial was registered with the University Hospital Medical Information Network (UMIN; no. 000009544).</p><p>Eligible patients were those with type 2 diabetes receiving treatment with sitagliptin (50&#x000a0;mg/day) and glimepiride (&#x02264;2.0&#x000a0;mg/day) with or without metformin at a stable dosage for at least 16&#x000a0;weeks, and aged &#x02265;20&#x000a0;years with a HbA1c level &#x02265;6.9% and no improvement in HbA1c within 12&#x000a0;weeks before dose&#x02010;up. Patients with type 1 diabetes, secondary diabetes, severe renal disease, severe hepatic disease, alcoholism, severe depression or a severe psychological condition, malignancy or abnormal hemoglobinemia were excluded. Patients who had received a blood transfusion within 4&#x000a0;months before the start of the study, and pregnant and nursing women were also excluded. Antidiabetic agents containing insulin, antihypertensive agents, statins or fibrates were not newly administered or their doses were not changed from 16&#x000a0;weeks before the start until the end of the study. The patients underwent baseline evaluation and were randomized 1:1 to receive 50&#x000a0;mg/day of sitagliptin dose&#x02010;up or 0.5&#x000a0;mg/day of glimepiride dose&#x02010;up using a computer&#x02010;generated allocation schedule. The patients were instructed to take sitagliptin or glimepiride each morning after breakfast, and were asked not to alter their lifestyle, including diet, exercise and habits, during the study.</p><p>The primary end&#x02010;point was the percentage change in HbA1c, calculated as: (post&#x02010;treatment value &#x02212; baseline value) &#x000d7; 100/baseline value, at each assessment during the follow&#x02010;up period. The secondary end&#x02010;points included the percentage changes in body mass index (BMI), fasting plasma glucose (FPG) and high molecular weight (HMW) adiponectin at each assessment. The follow&#x02010;up period was 12&#x000a0;weeks. Fasting serum levels of AA, EPA and DHA were measured before dose&#x02010;up of sitagliptin or glimepiride. Hypoglycemia was defined as any symptomatic event with cognitive or adrenergic signs with or without confirmation of plasma glucose. Severe hypoglycemia was defined as any symptomatic event requiring assistance by another person.</p><p>Blood samples were obtained between 08.30&#x000a0;h and 09.30&#x000a0;h after overnight fasting. HbA1c was measured by high&#x02010;performance liquid chromatography. The values of HbA1c are presented as National Glycohemoglobin Standardization Program values (%) calculated by the formula HbA1c (%)&#x000a0;=&#x000a0;1.02 &#x000d7; Japan Diabetes Society (%) + 0.25%, according to the recommendations of the Japan Diabetes Society<xref rid="jdi12151-bib-0013 jdi12151-bib-0014" ref-type="ref">13</xref>. Plasma insulin was measured by an electrochemiluminescence immunoassay (Eclusis insulin; Roche Diagnostics, Basel, Switzerland). Low&#x02010;density lipoprotein cholesterol levels were calculated using the formula of Friedewald <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0015" ref-type="ref">15</xref>. HMW adiponectin was measured by a latex turbidimetric immunoassay (Human adiponectin latex kit; Mitsubishi Chemical Medience Corporation, Tokyo, Japan). Serum AA, EPA and DHA were measured by gas chromatography by BML Inc. (Tokyo, Japan).</p></sec><sec id="jdi12151-sec-0008"><title>Statistical Analysis</title><p>Data are expressed as means&#x000a0;&#x000b1;&#x000a0;standard deviation. Changes in clinical parameters from before to 12&#x000a0;weeks after sitagliptin or glimepiride dose&#x02010;up were evaluated by Wilcoxon signed&#x02010;rank test. Differences in clinical parameters between the two groups were evaluated by Mann&#x02013;Whitney <italic>U</italic>&#x02010;test. To identify predictors of reductions of HbA1c after sitagliptin or glimepiride dose&#x02010;up, Spearman's correlation coefficient analysis was used to evaluate univariate correlations between improvement in HbA1c, and baseline levels of EPA, DHA, AA and EPA/AA ratio. <italic>P</italic>&#x02010;values &#x0003c;0.05 were considered to be statistically significant. Data analysis was carried out using SPSS version 11.5 for Windows (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results" id="jdi12151-sec-0009"><title>Results</title><p>There were no significant differences in baseline characteristics between the sitagliptin and glimepiride dose&#x02010;up groups (Table&#x000a0;<xref rid="jdi12151-tbl-0001" ref-type="table-wrap">1</xref>). All 50 participants completed the trial, and there were no clinically significant adverse events, except for hypoglycemia. Symptomatic hypoglycemia occurred in one patient in the glimepiride dose&#x02010;up group, but there was no severe hypoglycemic event in both groups. The final dosages of sitagliptin and glimepiride were 100&#x000a0;mg/day and 1.2&#x000a0;&#x000b1;&#x000a0;0.6&#x000a0;mg/day in the sitagliptin dose&#x02010;up group, and 50&#x000a0;mg/day and 1.7&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;mg/day in the glimepiride dose&#x02010;up group, respectively.</p><table-wrap id="jdi12151-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><title>Demographic and baseline characteristics of the participants</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">All</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sitagliptin dose&#x02010;up</th><th align="center" valign="bottom" rowspan="1" colspan="1">Glimepiride dose&#x02010;up</th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>&#x02010;value*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic> (Male/female)</td><td align="center" rowspan="1" colspan="1">50 (31/19)</td><td align="center" rowspan="1" colspan="1">25 (16/9)</td><td align="center" rowspan="1" colspan="1">25 (15/10)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.1&#x000a0;&#x000b1;&#x000a0;12.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63.9&#x000a0;&#x000b1;&#x000a0;10.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">62.4&#x000a0;&#x000b1;&#x000a0;14.3</td><td align="char" char="." rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.1&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.9&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.3&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="char" char="." rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">134&#x000a0;&#x000b1;&#x000a0;15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">132&#x000a0;&#x000b1;&#x000a0;14</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">136&#x000a0;&#x000b1;&#x000a0;16</td><td align="char" char="." rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">78&#x000a0;&#x000b1;&#x000a0;11</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">76&#x000a0;&#x000b1;&#x000a0;13</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80&#x000a0;&#x000b1;&#x000a0;9</td><td align="char" char="." rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15.6&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.8&#x000a0;&#x000b1;&#x000a0;4.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.4&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.77&#x000a0;&#x000b1;&#x000a0;0.19</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.74&#x000a0;&#x000b1;&#x000a0;0.18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.81&#x000a0;&#x000b1;&#x000a0;0.21</td><td align="char" char="." rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.4&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char" char="." rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">TC (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">182&#x000a0;&#x000b1;&#x000a0;27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">185&#x000a0;&#x000b1;&#x000a0;29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">178&#x000a0;&#x000b1;&#x000a0;23</td><td align="char" char="." rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">102&#x000a0;&#x000b1;&#x000a0;23</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">104&#x000a0;&#x000b1;&#x000a0;27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">99&#x000a0;&#x000b1;&#x000a0;18</td><td align="char" char="." rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">51&#x000a0;&#x000b1;&#x000a0;13</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">55&#x000a0;&#x000b1;&#x000a0;15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">47&#x000a0;&#x000b1;&#x000a0;10</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">143&#x000a0;&#x000b1;&#x000a0;32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">133&#x000a0;&#x000b1;&#x000a0;71</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">157&#x000a0;&#x000b1;&#x000a0;68</td><td align="char" char="." rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#x02010;HDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131&#x000a0;&#x000b1;&#x000a0;28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131&#x000a0;&#x000b1;&#x000a0;34</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131&#x000a0;&#x000b1;&#x000a0;22</td><td align="char" char="." rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">143&#x000a0;&#x000b1;&#x000a0;32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">142&#x000a0;&#x000b1;&#x000a0;32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145&#x000a0;&#x000b1;&#x000a0;33</td><td align="char" char="." rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">F&#x02010;IRI (&#x003bc;U/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.1&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.0&#x000a0;&#x000b1;&#x000a0;4.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.3&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">HMW adiponectin (&#x003bc;g/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char" char="." rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">AA (&#x003bc;g/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">196.9&#x000a0;&#x000b1;&#x000a0;41.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">190.2&#x000a0;&#x000b1;&#x000a0;31.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">203.3&#x000a0;&#x000b1;&#x000a0;49.4</td><td align="char" char="." rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">EPA (&#x003bc;g/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">82.6&#x000a0;&#x000b1;&#x000a0;42.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">85.0&#x000a0;&#x000b1;&#x000a0;33.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80.3&#x000a0;&#x000b1;&#x000a0;50.7</td><td align="char" char="." rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">DHA (&#x003bc;g/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">154.3&#x000a0;&#x000b1;&#x000a0;47.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">153.6&#x000a0;&#x000b1;&#x000a0;42.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">155.0&#x000a0;&#x000b1;&#x000a0;52.8</td><td align="char" char="." rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">EPA/AA ratio</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.45&#x000a0;&#x000b1;&#x000a0;0.27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.46&#x000a0;&#x000b1;&#x000a0;0.19</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.43&#x000a0;&#x000b1;&#x000a0;0.33</td><td align="char" char="." rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Dosage of glimepiride (mg/day)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char" char="." rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Metformin (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Dosage of metformin (mg/day)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">350&#x000a0;&#x000b1;&#x000a0;388</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">400&#x000a0;&#x000b1;&#x000a0;382</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">300&#x000a0;&#x000b1;&#x000a0;395</td><td align="char" char="." rowspan="1" colspan="1">0.24</td></tr></tbody></table><table-wrap-foot><fn id="jdi12151-note-0002"><p>AA, arachidonic acid; BMI, body mass index; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; F&#x02010;IRI, fasting immunoreactive insulin; FPG, fasting plasma glucose; HDL&#x02010;C, high&#x02010;density lipoprotein cholesterol; HMW adiponectin, high molecular weight adiponectin; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride. Mean&#x000a0;&#x000b1;&#x000a0;standard deviation values are shown. *<italic>P&#x02010;</italic>values for differences between the sitagliptin and glimepiride groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>There was no significant difference in the percentage change in HbA1c between the two groups (sitagliptin &#x02212;0.3&#x000a0;&#x000b1;&#x000a0;4.8% vs glimepiride &#x02212;3.0&#x000a0;&#x000b1;&#x000a0;5.3%, <italic>P</italic>&#x000a0;=&#x000a0;0.13; Figure&#x000a0;<xref rid="jdi12151-fig-0001" ref-type="fig">1</xref>). However, HbA1c significantly decreased from 7.5&#x000a0;&#x000b1;&#x000a0;0.6% at baseline to 7.3&#x000a0;&#x000b1;&#x000a0;0.7% after 12&#x000a0;weeks in the glimepiride dose&#x02010;up group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). In contrast, HbA1c in the sitagliptin dose&#x02010;up group had no significant change from baseline (7.3&#x000a0;&#x000b1;&#x000a0;0.5%) to after 12&#x000a0;weeks (7.3&#x000a0;&#x000b1;&#x000a0;0.7%).</p><fig fig-type="Figure" xml:lang="en" id="jdi12151-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Percentage change in glycated hemoglobin (<styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c) from baseline with 50&#x000a0;mg/day of sitagliptin dose&#x02010;up (black bar) and 0.5&#x000a0;mg/day of glimepiride dose&#x02010;up (white bar) during follow up. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 vs baseline.</p></caption><graphic xlink:href="jdi-5-320-g1"><alt-text>image</alt-text></graphic></fig><p>For the secondary end&#x02010;points, there were no significant differences between the groups in percentage change in BMI (sitagliptin 0.1&#x000a0;&#x000b1;&#x000a0;1.7% vs glimepiride 0.7&#x000a0;&#x000b1;&#x000a0;2.1%, <italic>P</italic>&#x000a0;=&#x000a0;0.32), FPG (3.5&#x000a0;&#x000b1;&#x000a0;18.6% vs 2.4&#x000a0;&#x000b1;&#x000a0;19.9%, <italic>P</italic>&#x000a0;=&#x000a0;0.41) and HMW adiponectin (8.7&#x000a0;&#x000b1;&#x000a0;18.9% vs 8.2&#x000a0;&#x000b1;&#x000a0;17.1%, <italic>P</italic>&#x000a0;=&#x000a0;0.62). However, in the glimepiride dose&#x02010;up group, HMW adiponectin increased significantly from 7.6&#x000a0;&#x000b1;&#x000a0;3.5 to 8.1&#x000a0;&#x000b1;&#x000a0;3.4&#x000a0;&#x003bc;U/mL after 12&#x000a0;weeks (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). In the sitagliptin dose&#x02010;up group, high&#x02010;density lipoprotein cholesterol (HDL&#x02010;C) increased significantly from 55&#x000a0;&#x000b1;&#x000a0;15 to 58&#x000a0;&#x000b1;&#x000a0;18&#x000a0;mg/dL after 12&#x000a0;weeks (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; Table&#x000a0;<xref rid="jdi12151-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jdi12151-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><title>Comparison of clinical parameters at baseline and at 12&#x000a0;weeks after additional administration of sitagiptin or glimepride</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" rowspan="2" valign="bottom" colspan="1"/><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Sitagliptin dose&#x02010;up (<italic>n</italic>&#x000a0;=&#x000a0;25)</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Glimepiride dose&#x02010;up (<italic>n</italic>&#x000a0;=&#x000a0;25)</th><th align="center" rowspan="2" valign="bottom" colspan="1"><italic>P</italic>&#x02010;value**</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">12&#x000a0;weeks after</th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>&#x02010;value*</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">12&#x000a0;weeks after</th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>&#x02010;value*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.9&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.0&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="char" char="." rowspan="1" colspan="1">0.81</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.3&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.5&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="char" char="." rowspan="1" colspan="1">0.05</td><td align="char" char="." rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">TC (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">185&#x000a0;&#x000b1;&#x000a0;29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">195&#x000a0;&#x000b1;&#x000a0;28</td><td align="char" char="." rowspan="1" colspan="1">0.07</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">178&#x000a0;&#x000b1;&#x000a0;23</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">185&#x000a0;&#x000b1;&#x000a0;39</td><td align="char" char="." rowspan="1" colspan="1">0.48</td><td align="char" char="." rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">104&#x000a0;&#x000b1;&#x000a0;27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">108&#x000a0;&#x000b1;&#x000a0;30</td><td align="char" char="." rowspan="1" colspan="1">0.49</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">99&#x000a0;&#x000b1;&#x000a0;18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">105&#x000a0;&#x000b1;&#x000a0;31</td><td align="char" char="." rowspan="1" colspan="1">0.66</td><td align="char" char="." rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">55&#x000a0;&#x000b1;&#x000a0;15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">58&#x000a0;&#x000b1;&#x000a0;18</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">47&#x000a0;&#x000b1;&#x000a0;10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">49&#x000a0;&#x000b1;&#x000a0;11</td><td align="char" char="." rowspan="1" colspan="1">0.18</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">133&#x000a0;&#x000b1;&#x000a0;71</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">142&#x000a0;&#x000b1;&#x000a0;73</td><td align="char" char="." rowspan="1" colspan="1">0.63</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">157&#x000a0;&#x000b1;&#x000a0;68</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">155&#x000a0;&#x000b1;&#x000a0;104</td><td align="char" char="." rowspan="1" colspan="1">0.27</td><td align="char" char="." rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#x02010;HDL&#x02010;C (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131&#x000a0;&#x000b1;&#x000a0;34</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">136&#x000a0;&#x000b1;&#x000a0;35</td><td align="char" char="." rowspan="1" colspan="1">0.24</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">131&#x000a0;&#x000b1;&#x000a0;22</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">136&#x000a0;&#x000b1;&#x000a0;36</td><td align="char" char="." rowspan="1" colspan="1">0.70</td><td align="char" char="." rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">142&#x000a0;&#x000b1;&#x000a0;32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">144&#x000a0;&#x000b1;&#x000a0;30</td><td align="char" char="." rowspan="1" colspan="1">0.31</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145&#x000a0;&#x000b1;&#x000a0;33</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">147&#x000a0;&#x000b1;&#x000a0;41</td><td align="char" char="." rowspan="1" colspan="1">0.70</td><td align="char" char="." rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">F&#x02010;IRI (&#x003bc;U/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.0&#x000a0;&#x000b1;&#x000a0;4.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.7&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="char" char="." rowspan="1" colspan="1">0.69</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.3&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.2&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="char" char="." rowspan="1" colspan="1">0.14</td><td align="char" char="." rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">HMW adiponectin (&#x003bc;g/mL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.0&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="char" char="." rowspan="1" colspan="1">0.10</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.1&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="char" char="." rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">0.47</td></tr></tbody></table><table-wrap-foot><fn id="jdi12151-note-0003"><p>BMI, body mass index; FPG, fasting plasma glucose; F&#x02010;IRI, fasting immunoreactive insulin; HDL&#x02010;C, high&#x02010;density lipoprotein cholesterol; HMW adiponectin, high molecular weight adiponectin; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. Mean&#x000a0;&#x000b1;&#x000a0;standard deviation values are shown. *<italic>P</italic>&#x02010;values for differences between data before and after 12&#x000a0;weeks of treatment. **<italic>P</italic>&#x02010;values for differences between the sitagliptin and glimepiride groups after 12&#x000a0;weeks of treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Correlations of AA, EPA, DHA and EPA/AA ratio with the percentage change in HbA1c determined by linear regression analysis are shown in Table&#x000a0;<xref rid="jdi12151-tbl-0003" ref-type="table-wrap">3</xref>. Simple linear regression analysis showed that baseline AA and the percentage change in HbA1c were negatively correlated in the sitagliptin dose&#x02010;up group (<italic>r</italic>&#x000a0;=&#x000a0;&#x02212;0.497, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05), but positively correlated in the glimepiride dose&#x02010;up group (<italic>r</italic>&#x000a0;=&#x000a0;0.531, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; Figure&#x000a0;<xref rid="jdi12151-fig-0002" ref-type="fig">2</xref>a). To further investigate the impact of AA on the efficacy of the two treatments, the participants in each group were divided into two subgroups by average level of AA (196.9&#x000a0;&#x003bc;g/mL), and percentage change in HbA1c in these subgroups was analyzed. In patients with AA &#x02264;196.9&#x000a0;&#x003bc;g/mL, the percentage change in HbA1c in the glimepiride dose&#x02010;up group (&#x02212;5.2&#x000a0;&#x000b1;&#x000a0;5.6%) significantly decreased more than that in the sitagliptin dose&#x02010;up group (0.3&#x000a0;&#x000b1;&#x000a0;4.6%; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). In contrast, in patients with AA &#x0003e;196.9&#x000a0;&#x003bc;g/mL, the percentage change in HbA1c in the sitagliptin dose&#x02010;up group (&#x02212;3.9&#x000a0;&#x000b1;&#x000a0;3.1%) significantly decreased more than that in the glimepiride dose&#x02010;up group (0.13&#x000a0;&#x000b1;&#x000a0;2.9%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; Figure&#x000a0;<xref rid="jdi12151-fig-0002" ref-type="fig">2</xref>b).</p><table-wrap id="jdi12151-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><title>Correlations of arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and eicosapentaenoic acid to arachidonic acid ratio with the percentage change in glycated hemoglobin determined by linear regression analysis</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>r</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>P</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Sitagliptin dose&#x02010;up</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AA</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.497</td><td align="char" char="." rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA</td><td align="char" char="." rowspan="1" colspan="1">0.059</td><td align="char" char="." rowspan="1" colspan="1">0.778</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">DHA</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.171</td><td align="char" char="." rowspan="1" colspan="1">0.414</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA/AA ratio</td><td align="char" char="." rowspan="1" colspan="1">0.225</td><td align="char" char="." rowspan="1" colspan="1">0.280</td></tr><tr><td align="left" colspan="3" rowspan="1">Glimepiride dose&#x02010;up</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AA</td><td align="char" char="." rowspan="1" colspan="1">0.531</td><td align="char" char="." rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.066</td><td align="char" char="." rowspan="1" colspan="1">0.756</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">DHA</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.023</td><td align="char" char="." rowspan="1" colspan="1">0.912</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA/AA ratio</td><td align="char" char="." rowspan="1" colspan="1">0.011</td><td align="char" char="." rowspan="1" colspan="1">0.959</td></tr></tbody></table><table-wrap-foot><fn id="jdi12151-note-0004"><p>AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdi12151-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(a) Correlations between the percentage changes in glycated hemoglobin (<styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c) and serum levels of arachidonic acid (<styled-content style="fixed-case">AA</styled-content>) at baseline with 50&#x000a0;mg/day of sitagliptin dose&#x02010;up (closed circles, dotted line) and 0.5&#x000a0;mg/day of glimepiride dose&#x02010;up (open circles, solid line). (b) Comparison of the percentage changes in glycated hemoglobin (<styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c) with between 50&#x000a0;mg/day of sitagliptin dose&#x02010;up (black bars) and 0.5&#x000a0;mg/day of glimepiride dose&#x02010;up (white bars), when the patients in each group were divided into two subgroups by average level of <styled-content style="fixed-case">AA</styled-content>.</p></caption><graphic xlink:href="jdi-5-320-g2"><alt-text>image</alt-text></graphic></fig></sec><sec sec-type="discussion" id="jdi12151-sec-0010"><title>Discussion</title><p>In the present study, no significant difference in the HbA1c&#x02010;lowering effects between 50&#x000a0;mg/day of sitagliptin dose&#x02010;up and 0.5&#x000a0;mg/day of glimepiride dose&#x02010;up was found in Japanese patients with type 2 diabetes controlled inadequately by a combination of sitagliptin and glimepiride. However, it showed that the dose&#x02010;up of glimepiride significantly decreased HbA1c in Japanese patients with type 2 diabetes controlled inadequately with both sitagliptin and glimepiride, and that, under these conditions, the percentage change in HbA1c by the addition of sitagliptin or glimepiride was negatively or positively correlated significantly with the serum level of AA, respectively.</p><p>Sitagliptin is administered as a single 100&#x02010;mg tablet in non&#x02010;Japanese patients<xref rid="jdi12151-bib-0016 jdi12151-bib-0017 jdi12151-bib-0018 jdi12151-bib-0019" ref-type="ref">16</xref>. In contrast, the usual dose of sitagliptin in Japan is 50&#x000a0;mg/day in patients with normal to mildly impaired renal function, because HbA1c, FPG and 2&#x02010;h postprandial plasma glucose do not differ significantly in 50, 100, and 200&#x000a0;mg/day sitagliptin monotherapy in Japanese patients<xref rid="jdi12151-bib-0020" ref-type="ref">20</xref>. Furthermore, the present study showed that the addition of 50&#x000a0;mg/day of sitagliptin did not significantly improve HbA1c levels in the participants treated with 50&#x000a0;mg/day of sitagliptin. These findings suggest that 50&#x000a0;mg/day of sitagliptin dose&#x02010;up might not be effective enough to lower HbA1c in patients with type 2 diabetes who are controlled inadequately by combination therapy with sitagliptin and glimepiride.</p><p>In the present study, a significant improvement of HDL&#x02010;C occurred by the addition of sitagliptin without the decrease in triglyceride (Table&#x000a0;<xref rid="jdi12151-tbl-0002" ref-type="table-wrap">2</xref>). The effect of sitagliptin on HDL&#x02010;C in subjects with type 2 diabetes is still controversial. Bergenstal <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0021" ref-type="ref">21</xref> and Charbonnel <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0022" ref-type="ref">22</xref> found that 100&#x000a0;mg/day sitagliptin significantly increased HDL&#x02010;C. However, a significant change in HDL&#x02010;C has not been found in Japanese patients receiving 50&#x000a0;mg/day sitagliptin monotherapy for type 2 diabetes<xref rid="jdi12151-bib-0023" ref-type="ref">23</xref>.</p><p>Interestingly, AA had a negative correlation with the decrease in HbA1c in the sitagliptin dose&#x02010;up group, but a positive correlation in the glimepiride dose&#x02010;up group. The exact reason for these findings is not clear, but one possible explanation is as follows. AA potentiates insulin secretion in &#x003b2;&#x02010;cells<xref rid="jdi12151-bib-0024 jdi12151-bib-0025 jdi12151-bib-0026 jdi12151-bib-0027 jdi12151-bib-0028 jdi12151-bib-0029 jdi12151-bib-0030 jdi12151-bib-0031" ref-type="ref">24</xref>, but prostaglandin E2 (PGE2), an AA metabolite, reduces insulin secretion through the inhibition of cyclic adenosine monophosphate (cAMP)&#x02010;accumulation and insulin sensitivity<xref rid="jdi12151-bib-0032 jdi12151-bib-0033 jdi12151-bib-0034 jdi12151-bib-0035 jdi12151-bib-0036 jdi12151-bib-0037 jdi12151-bib-0038" ref-type="ref">32</xref>. Furthermore, Ehses <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0028" ref-type="ref">28</xref> reported that GIP stimulated AA release from clonal &#x003b2;&#x02010;cells through stimulation of cAMP signaling. It is possible that an AA level might have increased after administration of sitagliptin in patients who are highly responsive to GIP. Therefore, a higher AA level before dose&#x02010;up might have resulted in a larger decrease in HbA1c in the sitagliptin dose&#x02010;up group, because an increase in GIP induced by sitagliptin dose&#x02010;up counteracted the inhibition of cAMP&#x02010;accumulation by PGE2. In contrast, Qi <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0039" ref-type="ref">39</xref> reported that AA elevated the intracellular Ca<sup>2+</sup> concentration in a dose&#x02010;dependent manner, and that glimepiride reduced the intracellular Ca<sup>2+</sup> elevation induced by AA in platelets. That report suggests that insulin secretion induced by glimepiride might be varied by the AA level. Therefore, it is speculated that the inhibitory effect of glimepiride on insulin secretion potentiated by AA might be lower in patients with lower AA treated with both sitagliptin and glimepiride. Thus, glimepiride reduced HbA1c more effectively in patients with lower AA. Clarification of this mechanism is important for understanding of the relationship between the decrease of HbA1c and the serum AA level. This will require further appropriate clinical and basic studies <italic>in vivo</italic> and <italic>in vitro</italic>.</p><p>Interestingly, in the range of reference values of AA (112.7~237.9&#x000a0;&#x003bc;g/mL), the percentage change in HbA1c in the glimepiride dose&#x02010;up group (&#x02212;3.9&#x000a0;&#x000b1;&#x000a0;5.4%) significantly decreased more than that in the sitagliptin dose&#x02010;up group (&#x02212;0.6&#x000a0;&#x000b1;&#x000a0;4.7%; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Therefore, from the viewpoint of HbA1c reduction, glimepiride dose&#x02010;up is more reasonable than sitagliptin dose&#x02010;up in most Japanese patients with type 2 diabetes controlled inadequately by sitagliptin and glimepiride in combination. However, when AA level is above the reference range, sitagliptin dose&#x02010;up is more effective than glimepiride dose&#x02010;up, because decreases in HbA1c were positively correlated with AA levels in patients receiving glimepiride dose&#x02010;up. These findings suggest that the serum AA level might provide the important information for selecting sitagliptin or glimepiride dose&#x02010;up in patients with type 2 diabetes receiving both sitagliptin and glimepiride treatment.</p><p>Iwasaki <italic>et&#x000a0;al</italic>.<xref rid="jdi12151-bib-0012" ref-type="ref">12</xref> found that the reduction of HbA1c by administration of DPP&#x02010;4 inhibitors as monotherapy significantly correlated with baseline levels of EPA and DHA, but not with that of AA, by the simple linear regression analysis, through unknown mechanisms. The background of the patients in the present study was different from that in the report by Iwasaki <italic>et&#x000a0;al</italic>., but the associations of alterations in HbA1c level with serum levels of polyunsaturated fatty acids in both studies is of interest. Clarification of the relationship between change of HbA1c and serum levels of AA, EPA, DHA, and EPA/AA ratio will require multivariate analysis in a large number of patients in a future study.</p><p>In conclusion, there was no significant difference in the HbA1c&#x02010;lowering effects between 50&#x000a0;mg/day sitagliptin dose&#x02010;up and 0.5&#x000a0;mg/day glimepiride dose&#x02010;up. However, a significant HbA1c reduction from baseline was observed in the glimepiride dose&#x02010;up group. The serum AA level is associated with HbA1c reduction in response to dose&#x02010;up with these drugs in patients with type 2 diabetes receiving combination therapy with sitagliptin and glimepiride.</p></sec></body><back><ack id="jdi12151-sec-0011"><title>Acknowledgements</title><p>The authors report no potential conflicts of interest relevant to this article.</p></ack><ref-list content-type="cited-references" id="jdi12151-bibl-0001"><title>References</title><ref id="jdi12151-bib-0001"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Nathan</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Buse</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Davidson</surname>
<given-names>MB</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source>Diabetes Care</source><year>2009</year>; <volume>32</volume>: <fpage>193</fpage>&#x02013;<lpage>203</lpage><pub-id pub-id-type="pmid">18945920</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0002"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Arai</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Matoba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hirao</surname>
<given-names>K</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross&#x02010;sectional survey of 15,652 patients</article-title>. <source>Endocr J</source><year>2010</year>; <volume>57</volume>: <fpage>499</fpage>&#x02013;<lpage>507</lpage><pub-id pub-id-type="pmid">20208396</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0003"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Tahrani</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Bailey</surname>
<given-names>CJ</given-names></string-name>, <string-name>
<surname>Del Prato</surname>
<given-names>S</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Management of type 2 diabetes: new and future developments in treatment</article-title>. <source>Lancet</source><year>2011</year>; <volume>378</volume>: <fpage>182</fpage>&#x02013;<lpage>197</lpage><pub-id pub-id-type="pmid">21705062</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0004"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Harashima</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Ogura</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>D</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Sitagliptin add&#x02010;on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes</article-title>. <source>Int J Clin Pract</source><year>2012</year>; <volume>66</volume>: <fpage>465</fpage>&#x02013;<lpage>476</lpage><pub-id pub-id-type="pmid">22512606</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0005"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Nonaka</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kakikawa</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>A</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source><year>2008</year>; <volume>79</volume>: <fpage>291</fpage>&#x02013;<lpage>298</lpage><pub-id pub-id-type="pmid">17933414</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0006"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Tajima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kadowaki</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Odawara</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control</article-title>. <source>Diabetol Int</source><year>2011</year>; <volume>2</volume>: <fpage>32</fpage>&#x02013;<lpage>44</lpage></mixed-citation></ref><ref id="jdi12151-bib-0007"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Hermansen</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kipnes</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>E</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of the dipeptidyl peptidase&#x02010;4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin</article-title>. <source>Diabetes Obes Metab</source><year>2007</year>; <volume>9</volume>: <fpage>733</fpage>&#x02013;<lpage>745</lpage><pub-id pub-id-type="pmid">17593236</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0008"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Vilsb&#x000f8;ll</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Rosenstock</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yki&#x02010;J&#x000e4;rvinen</surname></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source><year>2010</year>; <volume>12</volume>: <fpage>167</fpage>&#x02013;<lpage>177</lpage><pub-id pub-id-type="pmid">20092585</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0009"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Iwakura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tahara</surname>
<given-names>Y</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>A case of severe hypoglycemia induced by sitagliptin added to ongoing glimepiride therapy in patients with type 2 diabetes</article-title>. <source>J Jpn Diabetes Soc</source><year>2010</year>; <volume>53</volume>: <fpage>505</fpage>&#x02013;<lpage>508</lpage></mixed-citation></ref><ref id="jdi12151-bib-0010"><label>10</label><mixed-citation publication-type="book"><article-title>Sitagliptin post&#x02010;marketing surveillance study</article-title>. MSD KK, <publisher-name>Ono Pharmaceutical Co. Ltd.</publisher-name>, August 2010 (Japanese).</mixed-citation></ref><ref id="jdi12151-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous"><string-name><surname>Inagaki</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Iwakura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Iwamoto</surname>
<given-names>Y</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Committee on appropriate use of incretin&#x02010;based therapy</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nittokyo.or.jp/kinkyu_incretin100408m.html">http://www.nittokyo.or.jp/kinkyu_incretin100408m.html</ext-link></mixed-citation></ref><ref id="jdi12151-bib-0012"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Iwasaki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hoshian</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Tsuji</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Predicting efficacy of dipeptidyl peptidase&#x02010;4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels</article-title>. <source>J Diabetes Invest</source><year>2012</year>; <volume>3</volume>: <fpage>464</fpage>&#x02013;<lpage>467</lpage></mixed-citation></ref><ref id="jdi12151-bib-0013"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Seino</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Nanjo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tajima</surname>
<given-names>N</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Report of the Committee on the classification and diagnostic criteria of diabetes mellitus</article-title>. <source>J Diabetes Invest</source><year>2010</year>; <volume>1</volume>: <fpage>212</fpage>&#x02013;<lpage>228</lpage></mixed-citation></ref><ref id="jdi12151-bib-0014"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Kashiwagi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kasuga</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Araki</surname>
<given-names>E</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values</article-title>. <source>J Diabetes Invest</source><year>2012</year>; <volume>3</volume>: <fpage>39</fpage>&#x02013;<lpage>40</lpage></mixed-citation></ref><ref id="jdi12151-bib-0015"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Friedewald</surname>
<given-names>WT</given-names></string-name>, <string-name><surname>Levy</surname>
<given-names>RI</given-names></string-name>, <string-name><surname>Fredrickson</surname>
<given-names>DS</given-names></string-name>. <article-title>Estimation of the concentration of low&#x02010;density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title>. <source>Clin Chem</source><year>1972</year>; <volume>18</volume>: <fpage>499</fpage>&#x02013;<lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0016"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Scott</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and tolerability of the dipeptidyl peptidase&#x02010;4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes</article-title>. <source>Int J Clin Pract</source><year>2007</year>; <volume>61</volume>: <fpage>171</fpage>&#x02013;<lpage>180</lpage><pub-id pub-id-type="pmid">17156104</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0017"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Hanefeld</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Herman</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Sitagliptin Study 014 Investigators. Once&#x02010;daily sitagliptin, a dipeptidyl peptidase&#x02010;4 inhibitor, for the treatment of patients with type 2 diabetes</article-title>. <source>Curr Med Res Opin</source><year>2007</year>; <volume>23</volume>: <fpage>1329</fpage>&#x02013;<lpage>1339</lpage><pub-id pub-id-type="pmid">17559733</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0018"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Aschner</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kipnes</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Lunceford</surname>
<given-names>JK</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effect of the dipeptidyl peptidase&#x02010;4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source><year>2006</year>; <volume>29</volume>: <fpage>2632</fpage>&#x02013;<lpage>2637</lpage><pub-id pub-id-type="pmid">17130196</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0019"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Raz</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Hanefeld</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>L</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of the dipeptidyl peptidase&#x02010;4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus</article-title>. <source>Diabetologia</source><year>2006</year>; <volume>49</volume>: <fpage>2564</fpage>&#x02013;<lpage>2571</lpage><pub-id pub-id-type="pmid">17001471</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0020"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Iwamoto</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Taniguchi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nonaka</surname>
<given-names>K</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Dose&#x02010;ranging efficacy of sitagliptin, a dipeptidyl peptidase&#x02010;4 inhibitor, in Japanese patients with type 2 diabetes mellitus</article-title>. <source>Endocr J</source><year>2010</year>; <volume>57</volume>: <fpage>383</fpage>&#x02013;<lpage>394</lpage><pub-id pub-id-type="pmid">20332588</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0021"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Bergenstal</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Wysham</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Macconell</surname>
<given-names>L</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION&#x02010;2): a randomised trial</article-title>. <source>Lancet</source><year>2010</year>; <volume>376</volume>: <fpage>431</fpage>&#x02013;<lpage>439</lpage><pub-id pub-id-type="pmid">20580422</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0022"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Charbonnel</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Karasik</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of the dipeptidyl peptidase&#x02010;4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone</article-title>. <source>Diabetes Care</source><year>2006</year>; <volume>29</volume>: <fpage>2638</fpage>&#x02013;<lpage>2643</lpage><pub-id pub-id-type="pmid">17130197</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0023"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Iwamoto</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tajima</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kadowaki</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double&#x02010;blind trial</article-title>. <source>Diabetes Obes Metab</source><year>2010</year>; <volume>12</volume>: <fpage>613</fpage>&#x02013;<lpage>622</lpage><pub-id pub-id-type="pmid">20590736</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0024"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Ramanadham</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gross</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Turk</surname>
<given-names>J</given-names></string-name>. <article-title>Arachidonic acid induces an increase in the cytosolic calcium concentration in single pancreatic islet beta cells</article-title>. <source>Biochem Biophys Res Commun</source><year>1992</year>; <volume>184</volume>: <fpage>647</fpage>&#x02013;<lpage>653</lpage><pub-id pub-id-type="pmid">1575739</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0025"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Band</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Howell</surname>
<given-names>SL</given-names></string-name>. <article-title>Arachidonic acid&#x02010;induced insulin secretion from rat islets of Langerhans</article-title>. <source>J Mol Endocrinol</source><year>1992</year>; <volume>8</volume>: <fpage>95</fpage>&#x02013;<lpage>101</lpage><pub-id pub-id-type="pmid">1515022</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0026"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Turk</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gross</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Ramanadham</surname>
<given-names>S</given-names></string-name>. <article-title>Amplification of insulin secretion by lipid messengers</article-title>. <source>Diabetes</source><year>1993</year>; <volume>42</volume>: <fpage>367</fpage>&#x02013;<lpage>374</lpage><pub-id pub-id-type="pmid">8432406</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0027"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Simonsson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ahr&#x000e9;n</surname>
<given-names>B</given-names></string-name>. <article-title>Phospholipase A2 and its potential regulation of islet function</article-title>. <source>Int J Pancreatol</source><year>2000</year>; <volume>27</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="pmid">10811018</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0028"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Ehses</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Pederson</surname>
<given-names>RA</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>A new pathway for glucose&#x02010;dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP&#x02010;stimulated insulin secretion</article-title>. <source>J Biol Chem</source><year>2001</year>; <volume>276</volume>: <fpage>23667</fpage>&#x02013;<lpage>23673</lpage><pub-id pub-id-type="pmid">11323439</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0029"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Riahi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shamni</surname>
<given-names>O</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Role of lipid peroxidation and PPAR&#x02010;&#x003b4; in amplifying glucose&#x02010;stimulated insulin secretion</article-title>. <source>Diabetes</source><year>2011</year>; <volume>60</volume>: <fpage>2830</fpage>&#x02013;<lpage>2842</lpage><pub-id pub-id-type="pmid">21896929</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0030"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Cho</surname>
<given-names>YS</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>KY</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Protective effects of arachidonic acid against palmitic acid&#x02010;mediated lipotoxicity in HIT&#x02010;T15 cells</article-title>. <source>Mol Cell Biochem</source><year>2012</year>; <volume>364</volume>: <fpage>19</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="pmid">22203421</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0031"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Yeung&#x02010;Yam&#x02010;Wah</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Tse</surname>
<given-names>A</given-names></string-name>. <article-title>Arachidonic acid mobilizes Ca2+ from the endoplasmic reticulum and an acidic store in rat pancreatic &#x003b2; cells</article-title>. <source>Cell Calcium</source><year>2012</year>; <volume>51</volume>: <fpage>140</fpage>&#x02013;<lpage>148</lpage><pub-id pub-id-type="pmid">22197025</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0032"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Robertson</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Gavareski</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Porte</surname>
<given-names>D</given-names>
<suffix>Jr</suffix></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Inhibition of in vivo insulin secretion by prostaglandin E1</article-title>. <source>J Clin Invest</source><year>1974</year>; <volume>54</volume>: <fpage>310</fpage>&#x02013;<lpage>315</lpage><pub-id pub-id-type="pmid">4847247</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0033"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Robertson</surname>
<given-names>RP</given-names></string-name>. <article-title>Arachidonic acid metabolite regulation of insulin secretion</article-title>. <source>Diabetes Metab Rev</source><year>1986</year>; <volume>2</volume>: <fpage>261</fpage>&#x02013;<lpage>296</lpage><pub-id pub-id-type="pmid">3091336</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0034"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Seaquist</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Walseth</surname>
<given-names>TF</given-names></string-name>, <string-name><surname>Nelson</surname>
<given-names>DM</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pertussis toxin&#x02010;sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose&#x02010;induced insulin secretion in HIT cells</article-title>. <source>Diabetes</source><year>1989</year>; <volume>38</volume>: <fpage>1439</fpage>&#x02013;<lpage>1445</lpage><pub-id pub-id-type="pmid">2482818</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0035"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Dachicourt</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Serradas</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Giroix</surname>
<given-names>MH</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Decreased glucose&#x02010;induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP</article-title>. <source>Am J Physiol</source><year>1996</year>; <volume>271</volume>: <fpage>E725</fpage>&#x02013;<lpage>E732</lpage><pub-id pub-id-type="pmid">8897861</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0036"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Persaud</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Muller</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Belin</surname>
<given-names>VD</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>The role of arachidonic acid and its metabolites in insulin secretion from human islets of Langerhans</article-title>. <source>Diabetes</source><year>2007</year>; <volume>56</volume>: <fpage>197</fpage>&#x02013;<lpage>203</lpage><pub-id pub-id-type="pmid">17192482</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0037"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Luo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>MH</given-names></string-name>. <article-title>Eicosanoids, &#x003b2;&#x02010;cell function, and diabetes</article-title>. <source>Prostaglandins Other Lipid Mediat</source><year>2011</year>; <volume>95</volume>: <fpage>1</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="pmid">21757024</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0038"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Parazzoli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Harmon</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Vallerie</surname>
<given-names>SN</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Cyclooxygenase&#x02010;2, not microsomal prostaglandin E synthase&#x02010;1, is the mechanism for interleukin&#x02010;1&#x003b2;&#x02010;induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets</article-title>. <source>J Biol Chem</source><year>2012</year>; <volume>287</volume>: <fpage>32246</fpage>&#x02013;<lpage>32253</lpage><pub-id pub-id-type="pmid">22822059</pub-id></mixed-citation></ref><ref id="jdi12151-bib-0039"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Qi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ozaki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Satoh</surname>
<given-names>K</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Sulphonylurea agents inhibit platelet aggregation and [Ca2+]i elevation induced by arachidonic acid</article-title>. <source>Biochem Pharmacol</source><year>1995</year>; <volume>49</volume>: <fpage>1735</fpage>&#x02013;<lpage>1739</lpage><pub-id pub-id-type="pmid">7598735</pub-id></mixed-citation></ref></ref-list></back></article>